Readmission after pancreaticoduodenectomy: Birmingham score validation

HPB (Oxford). 2023 Feb;25(2):172-178. doi: 10.1016/j.hpb.2022.08.002. Epub 2022 Aug 20.

Abstract

Background: The Birmingham score predicts the risk of hospital readmission after pancreaticoduodenectomy (PD). This study aimed to validate the risk score in a different healthcare cohort.

Methods: From 2017 to 2021, 301 patients underwent PD. The Birmingham score was applied to 276 patients. Postoperative deceased patients (n = 7) or those requiring a completion of pancreatectomy (n = 18) were excluded.

Results: Forty-seven (17%) patients were readmitted after a median delay of 9 (range 1-49) days and stayed for 5 (range 1-27) days; 4 (8.5%) died during the hospital stay. The leading cause of readmission was a septic condition (53%), mostly resolved by medical treatment (77%). A multivariate analysis identified the occurrence of a clinically relevant postoperative pancreatic fistula, the score criteria, and the score itself as independent factors favouring readmission. Readmission rates in patients with low [n = 97 (35%)], intermediate [n = 98 (36%)], and high [n = 81 (29%)] scores were 5%, 17%, and 31%, respectively (P < 0.01).

Conclusion: This study confirmed the relevance and robustness of the Birmingham risk score. Patients with a high risk of readmission after PD, identified based on the score, were discharged to a partnership medical centre close to the pancreatic centre to plan readmission and avoid futile unplanned hospitalisation.

Trial registration: ClinicalTrials.gov NCT02871336.

Keywords: Birmingham risk score; Pancreaticoduodenectomy; Readmission.

MeSH terms

  • Humans
  • Pancreatectomy* / adverse effects
  • Pancreatic Fistula / etiology
  • Pancreaticoduodenectomy* / adverse effects
  • Patient Readmission
  • Postoperative Complications / etiology
  • Retrospective Studies
  • Risk Factors

Associated data

  • ClinicalTrials.gov/NCT02871336